A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phae III trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3-ITD AML BMT CTN Protocol 1506